HK Stock Market Move | HBM HOLDINGS-B (02142) rose over 9% in early trading, the buyback plan is progressing rapidly, and the drug for treating chronic obstructive pulmonary disease has been approved for clinical trials.

HBM HOLDINGS-B (02142) rose over 9% in the early trading session, up 9.39% to HKD 3.96 as of the time of writing, with a trading volume of HKD 13.87 million. On the news front, Hepalink announced on February 7th that the company has spent approximately HKD 9.533 million to repurchase 2.398 million shares. It is reported that in January, Hepalink announced its intention to repurchase shares worth no more than HKD 40 million. The rapid progress of the repurchase plan reflects the company's commitment to enhancing shareholder value and confidence in the company's long-term growth prospects. The company had previously stated that it may authorize further repurchase plans depending on market conditions. In addition, Hepalink announced that the group's fully human monoclonal antibody HBM9378/SKB378 (also known as WIN378) targeting thymic stromal lymphopoietin has obtained a new drug research application approval from the National Medical Products Administration Drug Evaluation Center to conduct clinical trials for the treatment of chronic obstructive pulmonary disease. It is reported that HBM9378/SKB378 is a joint development project between the company and Corindus, with both parties having rights in the Greater China region and multiple countries in Southeast Asia and West Asia.